Appili Therapeutics Inc. (APLIF)
APLIF Stock Price Chart
Explore Appili Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze APLIF price movements and trends.
APLIF Company Profile
Discover essential business fundamentals and corporate details for Appili Therapeutics Inc. (APLIF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Jan 2021
Employees
8.00
CEO
Donald D. Cilla Jr., Pharmd
Description
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
APLIF Financial Timeline
Browse a chronological timeline of Appili Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Feb 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$0.01 .
Earnings released on 25 Jun 2025
EPS came in at $0.00 , while revenue for the quarter reached -$8.85K .
Earnings released on 14 Feb 2025
EPS came in at -$0.00 , while revenue for the quarter reached $75.30K .
Earnings released on 14 Nov 2024
EPS came in at -$0.00 , while revenue for the quarter reached $3.46K .
Earnings released on 13 Aug 2024
EPS came in at -$0.01 .
Earnings released on 25 Jun 2024
EPS came in at -$0.01 matching the estimated -$0.01, while revenue for the quarter reached $8.61K .
Earnings released on 13 Feb 2024
EPS came in at -$0.00 surpassing the estimated -$0.01 by +90.50%, while revenue for the quarter reached $360.20K .
Earnings released on 13 Nov 2023
EPS came in at -$0.01 falling short of the estimated -$0.01 by -27.55%, while revenue for the quarter reached $249.03K .
Earnings released on 11 Aug 2023
EPS came in at -$0.01 falling short of the estimated -$0.01 by -62.87%.
Earnings released on 23 Jun 2023
EPS came in at -$0.02 falling short of the estimated -$0.01 by -35.23%, while revenue for the quarter reached $246.96K .
Earnings released on 14 Feb 2023
EPS came in at -$0.02 falling short of the estimated -$0.02 by -25.00%.
Earnings released on 10 Nov 2022
EPS came in at -$0.01 falling short of the estimated -$0.01 by -63.13%.
Earnings released on 12 Aug 2022
EPS came in at -$0.02 falling short of the estimated -$0.02 by -17.58%.
Earnings released on 29 Jun 2022
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%.
Earnings released on 14 Feb 2022
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%, while revenue for the quarter reached $1.09M , missing expectations by -0.17%.
Earnings released on 12 Nov 2021
EPS came in at -$0.14 falling short of the estimated -$0.07 by -100.00%.
Earnings released on 13 Aug 2021
EPS came in at -$0.10 falling short of the estimated -$0.06 by -66.67%.
Earnings released on 24 Jun 2021
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%.
Earnings released on 15 Feb 2021
EPS came in at -$0.05 falling short of the estimated -$0.03 by -83.82%.
Earnings released on 13 Nov 2020
EPS came in at -$0.03 surpassing the estimated -$0.06 by +50.00%.
APLIF Stock Performance
Access detailed APLIF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.